ReviewiLIVER2025
Convergent systemic therapy for liver metastases: Bridging primary tumor heterogeneity through shared pathways.
Review in iLIVER, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Liver metastases represent a major clinical challenge in oncology, often indicating advanced disease with complex management requirements. Despite originating from diverse primary tumors such as colorectal, pancreatic, and breast cancers, liver metastases exhibit shared biological behaviors influenced by the unique tumor microenvironment and immunosuppressive conditions of the liver. This review synthesizes advances in systemic, locoregional, and surgical therapies, demonstrating how shared mechanisms enable unified strategies such as pathway-targeted agents and immunotherapy-radiotherapy combinations, even amid primary tumor heterogeneity. Multidisciplinary team collaboration is critical for optimizing individualized treatment plans, balancing locoregional and systemic treatments to convert unresectable cases and improve the survival rate. We propose a paradigm of precision convergence "harmonizing tumor therapies with lineage-specific adjustments" guided by the principle of "commonalities in biology, divergences in context".
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.